The stock will trade on Phase 2 execution milestones rather than financial results. Key catalysts to monitor: first patient enrollment in ASCENTRA-UC (expected 2H 2026), IND submission for ASCENTRA-CD (2H 2026), and any early efficacy signals from the Phase 2 program. The $125M cash runway removes near-term financing risk but the pre-revenue profile means binary Phase 2 readout risk dominates.
Price Chart
Executive Summary
Palisade Bio reported Q2 2026 results in line with Street consensus (EPS -$0.05 vs -$0.05 est), with no revenue surprise. The filing is dominated by operational progress — FDA IND clearance, Phase 2 ASCENTRA-UC trial commencement expected in 2H 2026, and a strong $125.2M cash position funding through key Phase 2 readouts in 2027-2028. The $0.5M milestone license revenue from Newsoara is a modest positive, but the pre-revenue clinical-stage nature of the company makes this a pipeline-progress update rather than a financial catalyst.
Key Financial Metrics
Key Facts
- Net loss of $10.6M ($0.05/share) for Q2 2026 vs $2.8M ($0.58/share) in Q2 2025
- Cash and cash equivalents of $125.2M as of June 30, 2026, down from $133.4M at Dec 31, 2025
- FDA clearance of IND for Phase 2 ASCENTRA-UC trial of PALI-2108 received; enrollment expected 2H 2026
- Phase 2 UC primary efficacy readout expected 2H 2027; Phase 2 CD IND expected 2H 2026
- Recognized $0.5M license revenue milestone from Newsoara co-development agreement
- Phase 1 data showed 5/5 UC patients achieved clinical response, 2/5 clinical remission; FSCD cohort showed ~47.5% mean SES-CD reduction
Financial Impact
Net loss widened to $10.6M from $2.8M YoY driven by increased R&D ($7.4M vs $1.7M) and G&A ($4.8M vs $1.2M) expenses as the company scales for Phase 2. Cash burn of $8.2M in H1 2026 vs $4.4M in H1 2025. $125.2M cash runway sufficient through Phase 2 readouts.
Risk Factors
- Phase 2 trial failure or disappointing efficacy data
- Competition from approved IBD therapies (JAK inhibitors, anti-integrins, IL-23 inhibitors)
- Dilution risk if additional capital needed before Phase 2 readouts
- Small Phase 1 sample size (n=5 per cohort) may not predict Phase 2 results
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001357459-26-000017 |
| Document: pali-20260810.htm | 0001357459-26-000017 |
| Document: 0001357459-26-000017-index-headers.html | 0001357459-26-000017 |
| Document: 0001357459-26-000017-index.html | 0001357459-26-000017 |
| Document: 0001357459-26-000017.txt | 0001357459-26-000017 |
| 8-K Data (Synthetic) | 0001357459-26-000017 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $2.14 $2.05 | ▼ −4.21% | ▼ −3.15% | $1.45 (−32.48%) |
Jul 10, 2026 11w ago | Insider Cluster | $1.89 $2.10 | ▲ +11.11% | ▲ +7.93% | $1.45 (−23.54%) |
Jul 8, 2026 12w ago | Insider Cluster | $1.97 $2.09 | ▲ +6.09% | ▲ +3.85% | $1.45 (−26.65%) |
Jun 11, 2026 16w ago | 8-K | $1.71 $1.96 | ▲ +14.62% | ▲ +12.84% | $1.45 (−15.50%) |
May 22, 2026 19w ago | EFFECT | $1.95 $1.89 | ▼ −3.08% | ▼ −1.66% | $1.45 (−25.90%) |
May 12, 2026 20w ago | S-3 | $1.87 $1.78 | ▼ −4.81% | ▼ −4.20% | $1.45 (−22.73%) |
Apr 29, 2026 22w ago | DEFA14A | $2.00 $2.12 | ▲ +6.00% | ▲ +0.77% | $1.45 (−27.75%) |
Apr 2, 2026 26w ago | 8-K | $1.89 $2.00 | ▲ +5.82% | ▼ −4.06% | $1.45 (−23.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access